1
|
Kuric M, Beck S, Schneider D, Rindt W, Evers M, Meißner-Weigl J, Zeck S, Krug M, Herrmann M, Hartmann TN, Leich E, Rudert M, Docheva D, Seckinger A, Hose D, Jundt F, Ebert R. Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics. Cancer Res Commun 2024; 4:1150-1164. [PMID: 38598843 PMCID: PMC11057410 DOI: 10.1158/2767-9764.crc-23-0411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Revised: 02/08/2024] [Accepted: 04/08/2024] [Indexed: 04/12/2024]
Abstract
Multiple myeloma involves early dissemination of malignant plasma cells across the bone marrow; however, the initial steps of dissemination remain unclear. Human bone marrow-derived mesenchymal stromal cells (hMSC) stimulate myeloma cell expansion (e.g., IL6) and simultaneously retain myeloma cells via chemokines (e.g., CXCL12) and adhesion factors. Hence, we hypothesized that the imbalance between cell division and retention drives dissemination. We present an in vitro model using primary hMSCs cocultured with INA-6 myeloma cells. Time-lapse microscopy revealed proliferation and attachment/detachment dynamics. Separation techniques (V-well adhesion assay and well plate sandwich centrifugation) were established to isolate MSC-interacting myeloma subpopulations that were characterized by RNA sequencing, cell viability, and apoptosis. Results were correlated with gene expression data (n = 837) and survival of patients with myeloma (n = 536). On dispersed hMSCs, INA-6 saturate hMSC surface before proliferating into large homotypic aggregates, from which single cells detached completely. On confluent hMSCs, aggregates were replaced by strong heterotypic hMSC-INA-6 interactions, which modulated apoptosis time dependently. Only INA-6 daughter cells (nMA-INA6) detached from hMSCs by cell division but sustained adherence to hMSC-adhering mother cells (MA-INA6). Isolated nMA-INA6 indicated hMSC autonomy through superior viability after IL6 withdrawal and upregulation of proliferation-related genes. MA-INA6 upregulated adhesion and retention factors (CXCL12), that, intriguingly, were highly expressed in myeloma samples from patients with longer overall and progression-free survival, but their expression decreased in relapsed myeloma samples. Altogether, in vitro dissemination of INA-6 is driven by detaching daughter cells after a cycle of hMSC-(re)attachment and proliferation, involving adhesion factors that represent a bone marrow-retentive phenotype with potential clinical relevance. SIGNIFICANCE Novel methods describe in vitro dissemination of myeloma cells as detachment of daughter cells after cell division. Myeloma adhesion genes were identified that counteract in vitro detachment with potential clinical relevance.
Collapse
Affiliation(s)
- Martin Kuric
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Susanne Beck
- University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany
| | - Doris Schneider
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Wyonna Rindt
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
| | - Marietheres Evers
- University of Würzburg, Institute of Pathology, Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - Jutta Meißner-Weigl
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Sabine Zeck
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Melanie Krug
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Marietta Herrmann
- University Hospital Würzburg, IZKF Research Group Tissue Regeneration in Musculoskeletal Diseases, Würzburg, Germany
| | - Tanja Nicole Hartmann
- Department of Internal Medicine I, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany
| | - Ellen Leich
- University of Würzburg, Institute of Pathology, Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - Maximilian Rudert
- Orthopedic Department, Clinic König-Ludwig-Haus, University of Würzburg, Würzburg, Germany
| | - Denitsa Docheva
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Anja Seckinger
- Department of Hematology and Immunology, Vrije Universiteit Brussel, Jette, Belgium
| | - Dirk Hose
- Department of Hematology and Immunology, Vrije Universiteit Brussel, Jette, Belgium
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
| | - Regina Ebert
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| |
Collapse
|
2
|
Maichl DS, Kirner JA, Beck S, Cheng WH, Krug M, Kuric M, Ade CP, Bischler T, Jakob F, Hose D, Seckinger A, Ebert R, Jundt F. Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival. Blood Cancer J 2023; 13:134. [PMID: 37669941 PMCID: PMC10480158 DOI: 10.1038/s41408-023-00907-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 08/04/2023] [Accepted: 08/24/2023] [Indexed: 09/07/2023] Open
Affiliation(s)
- Daniela Simone Maichl
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany
| | - Julius Arthur Kirner
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany
| | - Susanne Beck
- Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany
| | - Wen-Hui Cheng
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany
| | - Melanie Krug
- Bernhard-Heine-Center for Locomotion Research, Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Friedrich-Bergius-Ring 15, 97076, Würzburg, Germany
| | - Martin Kuric
- Bernhard-Heine-Center for Locomotion Research, Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Friedrich-Bergius-Ring 15, 97076, Würzburg, Germany
| | - Carsten Patrick Ade
- Department of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, Am Hubland, 97074, Würzburg, Germany
| | - Thorsten Bischler
- Core Unit Systems Medicine, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany
| | - Franz Jakob
- Bernhard-Heine-Center for Locomotion Research, Orthopedic Department, University of Würzburg, Brettreichstrasse 11, 97074, Würzburg, Germany
| | - Dirk Hose
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brusells, Belgium
| | - Anja Seckinger
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brusells, Belgium
| | - Regina Ebert
- Bernhard-Heine-Center for Locomotion Research, Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Friedrich-Bergius-Ring 15, 97076, Würzburg, Germany
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany.
| |
Collapse
|
3
|
Grunz JP, Kunz AS, Baumann FT, Hasenclever D, Sieren MM, Heldmann S, Bley TA, Einsele H, Knop S, Jundt F. Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma. Cancers (Basel) 2023; 15:4008. [PMID: 37568823 PMCID: PMC10417114 DOI: 10.3390/cancers15154008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 07/28/2023] [Accepted: 08/04/2023] [Indexed: 08/13/2023] Open
Abstract
Multiple myeloma (MM) frequently induces persisting osteolytic manifestations despite hematologic treatment response. This study aimed to establish a biometrically valid study endpoint for bone remineralization through quantitative and qualitative analyses in sequential CT scans. Twenty patients (seven women, 58 ± 8 years) with newly diagnosed MM received standardized induction therapy comprising the anti-SLAMF7 antibody elotuzumab, carfilzomib, lenalidomide, and dexamethasone (E-KRd). All patients underwent whole-body low-dose CT scans before and after six cycles of E-KRd. Two radiologists independently recorded osteolytic lesion sizes, as well as the presence of cortical destruction, pathologic fractures, rim and trabecular sclerosis. Bland-Altman analyses and Krippendorff's α were employed to assess inter-reader reliability, which was high for lesion size measurement (standard error 1.2 mm) and all qualitative criteria assessed (α ≥ 0.74). After six cycles of E-KRd induction, osteolytic lesion size decreased by 22% (p < 0.001). While lesion size response did not correlate with the initial lesion size at baseline imaging (Pearson's r = 0.144), logistic regression analysis revealed that the majority of responding osteolyses exhibited trabecular sclerosis (p < 0.001). The sum of osteolytic lesion sizes on sequential CT scans defines a reliable study endpoint to characterize bone remineralization. Patient level response is strongly associated with the presence of trabecular sclerosis.
Collapse
Affiliation(s)
- Jan-Peter Grunz
- Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany; (A.S.K.); (T.A.B.)
| | - Andreas Steven Kunz
- Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany; (A.S.K.); (T.A.B.)
| | - Freerk T. Baumann
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University Hospital of Cologne, Kerpener Straße 62, 50937 Cologne, Germany;
| | - Dirk Hasenclever
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Härtelstraße 16–18, 04107 Leipzig, Germany;
| | - Malte Maria Sieren
- Department of Radiology and Nuclear Medicine, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23562 Lübeck, Germany;
- Institute of Interventional Radiology, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23562 Lübeck, Germany
| | - Stefan Heldmann
- Fraunhofer Institute for Digital Medicine MEVIS, Maria-Goeppert-Straße 3, 23562 Lübeck, Germany;
| | - Thorsten Alexander Bley
- Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany; (A.S.K.); (T.A.B.)
| | - Hermann Einsele
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany; (H.E.); (S.K.); (F.J.)
| | - Stefan Knop
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany; (H.E.); (S.K.); (F.J.)
- Department of Internal Medicine, Klinikum Nürnberg Nord, Prof.-Ernst-Nathan-Str. 1, 90419 Nürnberg, Germany
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany; (H.E.); (S.K.); (F.J.)
| |
Collapse
|
4
|
Evers M, Schreder M, Stühmer T, Jundt F, Ebert R, Hartmann TN, Altenbuchinger M, Rudelius M, Kuric M, Rindt WD, Steinbrunn T, Langer C, Heredia-Guerrero SC, Einsele H, Bargou RC, Rosenwald A, Leich E. Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma. Blood Cancer J 2023; 13:43. [PMID: 36959208 PMCID: PMC10036560 DOI: 10.1038/s41408-023-00817-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/02/2023] [Accepted: 03/10/2023] [Indexed: 03/25/2023] Open
Affiliation(s)
| | - Martin Schreder
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
- First Department of Medicine, Klinik Ottakring, Vienna, Austria
| | - Thorsten Stühmer
- Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
- Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany
| | - Regina Ebert
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Tanja Nicole Hartmann
- Department of Internal Medicine I, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany
| | - Michael Altenbuchinger
- Department of Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany
| | - Martina Rudelius
- Institute of Pathology, University of Würzburg, Würzburg, Germany
- Institute of Pathology, Ludwig-Maximilians-University München, München, Germany
| | - Martin Kuric
- Department of Musculoskeletal Tissue Regeneration, University of Würzburg, Würzburg, Germany
| | - Wyonna Darleen Rindt
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
| | - Torsten Steinbrunn
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Christian Langer
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
| | | | - Hermann Einsele
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany
| | - Ralf Christian Bargou
- Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany
| | - Andreas Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg, Germany
- Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany
| | - Ellen Leich
- Institute of Pathology, University of Würzburg, Würzburg, Germany.
- Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
| |
Collapse
|
5
|
Ziouti F, Rummler M, Steyn B, Thiele T, Seliger A, Duda GN, Bogen B, Willie BM, Jundt F. Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease. Int J Mol Sci 2021; 22:ijms22083840. [PMID: 33917250 PMCID: PMC8067978 DOI: 10.3390/ijms22083840] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 03/28/2021] [Accepted: 04/01/2021] [Indexed: 02/07/2023] Open
Abstract
Limiting bone resorption and regenerating bone tissue are treatment goals in myeloma bone disease (MMBD). Physical stimuli such as mechanical loading prevent bone destruction and enhance bone mass in the MOPC315.BM.Luc model of MMBD. It is unknown whether treatment with the Bruton’s tyrosine kinase inhibitor CC-292 (spebrutinib), which regulates osteoclast differentiation and function, augments the anabolic effect of mechanical loading. CC-292 was administered alone and in combination with axial compressive tibial loading in the MOPC315.BM.Luc model for three weeks. However, neither CC-292 alone nor its use in combination with mechanical loading was more effective in reducing osteolytic bone disease or rescuing bone mass than mechanical stimuli alone, as evidenced by microcomputed tomography (microCT) and histomorphometric analysis. Further studies are needed to investigate novel anti-myeloma and anti-resorptive strategies in combination with physical stimuli to improve treatment of MMBD.
Collapse
Affiliation(s)
- Fani Ziouti
- Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany;
| | - Maximilian Rummler
- Research Centre, Shriners Hospital for Children-Canada, Montreal, QC H4A 0A9, Canada; (M.R.); (B.S.)
- Department of Pediatric Surgery, McGill University, Montreal, QC H4A 3J1, Canada
- Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité−Universitätsmedizin Berlin, 13353 Berlin, Germany; (T.T.); (A.S.); (G.N.D.)
| | - Beatrice Steyn
- Research Centre, Shriners Hospital for Children-Canada, Montreal, QC H4A 0A9, Canada; (M.R.); (B.S.)
- Department of Pediatric Surgery, McGill University, Montreal, QC H4A 3J1, Canada
| | - Tobias Thiele
- Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité−Universitätsmedizin Berlin, 13353 Berlin, Germany; (T.T.); (A.S.); (G.N.D.)
| | - Anne Seliger
- Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité−Universitätsmedizin Berlin, 13353 Berlin, Germany; (T.T.); (A.S.); (G.N.D.)
| | - Georg N. Duda
- Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité−Universitätsmedizin Berlin, 13353 Berlin, Germany; (T.T.); (A.S.); (G.N.D.)
| | - Bjarne Bogen
- Institute of Clinical Medicine, University of Oslo and Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway;
| | - Bettina M. Willie
- Research Centre, Shriners Hospital for Children-Canada, Montreal, QC H4A 0A9, Canada; (M.R.); (B.S.)
- Department of Pediatric Surgery, McGill University, Montreal, QC H4A 3J1, Canada
- Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité−Universitätsmedizin Berlin, 13353 Berlin, Germany; (T.T.); (A.S.); (G.N.D.)
- Correspondence: (B.M.W.); (F.J.)
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany;
- Comprehensive Cancer Center Mainfranken, 97080 Würzburg, Germany
- Correspondence: (B.M.W.); (F.J.)
| |
Collapse
|
6
|
Rummler M, Ziouti F, Bouchard AL, Brandl A, Duda GN, Bogen B, Beilhack A, Lynch ME, Jundt F, Willie BM. Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease. Acta Biomater 2021; 119:247-258. [PMID: 33130307 DOI: 10.1016/j.actbio.2020.10.041] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Revised: 10/05/2020] [Accepted: 10/27/2020] [Indexed: 02/08/2023]
Abstract
Bone continually adapts to changing external loading conditions via (re)modeling (modeling and remodeling) processes. While physical activity is known to beneficially enhance bone mass in healthy individuals, little is known in how physical stimuli affect osteolytic bone destruction in patients suffering from multiple myeloma bone disease. Multiple myeloma (MM) is caused by malignant plasma cells in the bone marrow, shifting the balance in bone remodeling towards massive resorption. We hypothesized that in vivo tibial mechanical loading has anabolic effects in mice with locally injected MOPC315.BM.Luc cells. Conventional microCT analysis revealed enhanced cortical bone mass and microstructure in loaded compared to nonloaded mice. State-of-the-art time-lapse microCT based image analysis demonstrated bone (re)modeling processes at the endosteal and periosteal surfaces as the underlying causes of increased bone mass. Loading prevented the progression and development of osteolytic destruction. Physical stimuli also diminished local MM cell growth and dissemination evidenced by quantification of MM cell-specific immunoglobulin A levels in the serum of mice and by bioluminescence analysis. These data indicate that mechanical loading not only rescues the bone phenotype, but also exerts cell-extrinsic anti-myeloma effects in the MOPC315.BM.Luc model. In conclusion, the use of physical stimuli should be further investigated as an anabolic treatment for osteolytic bone destruction in patients with MM.
Collapse
|
7
|
Seefried L, Genest F, Strömsdörfer J, Engelmann B, Lapa C, Jakob F, Baumann FT, Sperlich B, Jundt F. Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance. J Bone Oncol 2020; 25:100323. [PMID: 33083217 PMCID: PMC7551327 DOI: 10.1016/j.jbo.2020.100323] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 09/17/2020] [Accepted: 09/21/2020] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVE Monoclonal Gammopathy of Undetermined Significance (MGUS) is a risk factor for reduced physical performance, osteoporosis, and fractures due to compromised musculoskeletal metabolism. In this condition it is unknown whether whole-body vibration (WBV) exercise favorably alters physical performance and bone metabolism. METHODS To evaluate the effect of three-months WBV exercise (30 min; 2x/week) including an optional three-month extension on physical performance, bone metabolism and bone mineral density. Endpoints included functional assessments, bone turnover markers and bone mineral density assessed by peripheral quantitative computed tomography of the tibia. RESULTS Fifteen MGUS patients (median age 62.0, nine female) completed the first three months of which ten completed the three-month extension. Measures of physical functioning including chair rise test, timed up and go and 6-minute walk test improved (p = 0.007; p = 0.009; p = 0.005) after three and six months of WBV exercise. Total tibial bone mineral density remained unaltered (p > 0.05). WBV exercise tended to increase levels of sclerostin (p = 0.093) with a transient increase in osteoclast resorption markers (N-terminal telopeptide of collagen type 1, tartrate resistant acid phosphatase 5b) after three months while Dickkopf-1 (p = 0.093), procollagen I N-terminal propeptide (p = 0.074) and total alkaline phosphatase (p = 0.016) appeared to decline. No exercise-related adverse events were reported. CONCLUSION WBV exercise in MGUS patients improves indicators of physical performance. Observed trends in bone turnover markers and changes in distal tibial bone mineral density may indicate a regulatory effect of WBV exercise on bone metabolism and warrants further evaluation by large scale studies.
Collapse
Affiliation(s)
- Lothar Seefried
- Orthopedic Department, University of Würzburg, Würzburg, Germany
| | - Franca Genest
- Orthopedic Department, University of Würzburg, Würzburg, Germany
| | - Johanna Strömsdörfer
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
| | - Bernhard Engelmann
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
| | - Constantin Lapa
- Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
| | - Franz Jakob
- Orthopedic Department, University of Würzburg, Würzburg, Germany
- Orthopedic Center for Musculoskeletal Research, Experimental and Clinical Osteology, Würzburg, Germany
| | - Freerk T Baumann
- Department 1 of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, University Hospital of Cologne, Cologne, Germany
| | - Billy Sperlich
- Integrative and Experimental Training Science, Department of Sport Science, University of Würzburg, Würzburg, Germany
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany
| |
Collapse
|
8
|
Cordas Dos Santos D, Erickson N, Gerland L, Jundt F, Theurich S. [Primary and Secondary Prevention of Multiple Myeloma - Lifestyle Factors and Supportive Measures]. Dtsch Med Wochenschr 2020; 145:836-842. [PMID: 32557486 DOI: 10.1055/a-1009-1363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Lifestyle factors such as diet, physical activity and exposure to noxious agents are modifiable factors that have a significant impact on the state of health and life expectancy of humans. The following article is intended to provide an overview of current knowledge on the influence of these lifestyle factors on the development and progression of multiple myeloma and is dedicated to the question of the extent to which prevention strategies can be usefully applied.
Collapse
|
9
|
Cordas dos Santos D, Erickson N, Gerland L, Jundt F, Theurich S. Primär- und Sekundärprävention des Multiplen Myeloms. Dtsch Med Wochenschr 2020; 145:e94. [DOI: 10.1055/a-1221-3527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Herrmann M, Engelke K, Ebert R, Müller-Deubert S, Rudert M, Ziouti F, Jundt F, Felsenberg D, Jakob F. Interactions between Muscle and Bone-Where Physics Meets Biology. Biomolecules 2020; 10:biom10030432. [PMID: 32164381 PMCID: PMC7175139 DOI: 10.3390/biom10030432] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 02/27/2020] [Accepted: 03/05/2020] [Indexed: 02/06/2023] Open
Abstract
Muscle and bone interact via physical forces and secreted osteokines and myokines. Physical forces are generated through gravity, locomotion, exercise, and external devices. Cells sense mechanical strain via adhesion molecules and translate it into biochemical responses, modulating the basic mechanisms of cellular biology such as lineage commitment, tissue formation, and maturation. This may result in the initiation of bone formation, muscle hypertrophy, and the enhanced production of extracellular matrix constituents, adhesion molecules, and cytoskeletal elements. Bone and muscle mass, resistance to strain, and the stiffness of matrix, cells, and tissues are enhanced, influencing fracture resistance and muscle power. This propagates a dynamic and continuous reciprocity of physicochemical interaction. Secreted growth and differentiation factors are important effectors of mutual interaction. The acute effects of exercise induce the secretion of exosomes with cargo molecules that are capable of mediating the endocrine effects between muscle, bone, and the organism. Long-term changes induce adaptations of the respective tissue secretome that maintain adequate homeostatic conditions. Lessons from unloading, microgravity, and disuse teach us that gratuitous tissue is removed or reorganized while immobility and inflammation trigger muscle and bone marrow fatty infiltration and propagate degenerative diseases such as sarcopenia and osteoporosis. Ongoing research will certainly find new therapeutic targets for prevention and treatment.
Collapse
Affiliation(s)
- Marietta Herrmann
- Orthopedic Department, Bernhard-Heine-Center for Locomotion Research, IZKF Research Group Tissue regeneration in musculoskeletal diseases, University Hospital Würzburg, University of Wuerzburg, 97070 Würzburg, Germany;
| | - Klaus Engelke
- Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany;
| | - Regina Ebert
- Orthopedic Department, Bernhard-Heine-Center for Locomotion Research, University of Würzburg, IGZ, 97076 Würzburg, Germany; (R.E.)
| | - Sigrid Müller-Deubert
- Orthopedic Department, Bernhard-Heine-Center for Locomotion Research, University of Würzburg, IGZ, 97076 Würzburg, Germany; (R.E.)
| | - Maximilian Rudert
- Orthopedic Department, Bernhard-Heine-Center for Locomotion Research, University of Würzburg, 97074 Würzburg, Germany;
| | - Fani Ziouti
- Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany; (F.Z.); (F.J.)
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany; (F.Z.); (F.J.)
| | - Dieter Felsenberg
- Privatpraxis für Muskel- und Knochenkrankheiten, 12163 Berlin Germany;
| | - Franz Jakob
- Orthopedic Department, Bernhard-Heine-Center for Locomotion Research, University of Würzburg, IGZ, 97076 Würzburg, Germany; (R.E.)
- Orthopedic Department, Bernhard-Heine-Center for Locomotion Research, University of Würzburg, 97074 Würzburg, Germany;
- Correspondence:
| |
Collapse
|
11
|
Zilkowski I, Ziouti F, Schulze A, Hauck S, Schmidt S, Mainz L, Sauer M, Albrecht K, Jundt F, Groll J. Nanogels Enable Efficient miRNA Delivery and Target Gene Downregulation in Transfection-Resistant Multiple Myeloma Cells. Biomacromolecules 2018; 20:916-926. [DOI: 10.1021/acs.biomac.8b01553] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Ilona Zilkowski
- Department for Functional Materials in Medicine and Dentistry and Bavarian Polymer Institute, University of Würzburg, Pleicherwall 2, 97070 Würzburg, Germany
| | - Fani Ziouti
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany
| | - Andres Schulze
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany
| | - Stefanie Hauck
- Department for Functional Materials in Medicine and Dentistry and Bavarian Polymer Institute, University of Würzburg, Pleicherwall 2, 97070 Würzburg, Germany
| | - Stefanie Schmidt
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany
| | - Laura Mainz
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany
| | - Markus Sauer
- Chair for Biotechnology and Biophysics, University of Würzburg, Am Hubland, 97074 Würzburg, Germany
| | - Krystyna Albrecht
- Department for Functional Materials in Medicine and Dentistry and Bavarian Polymer Institute, University of Würzburg, Pleicherwall 2, 97070 Würzburg, Germany
| | - Franziska Jundt
- Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080 Würzburg, Germany
| | - Jürgen Groll
- Department for Functional Materials in Medicine and Dentistry and Bavarian Polymer Institute, University of Würzburg, Pleicherwall 2, 97070 Würzburg, Germany
| |
Collapse
|
12
|
Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Dörken B, le Coutre P. Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. Leuk Lymphoma 2015; 56:2105-13. [PMID: 25363400 DOI: 10.3109/10428194.2014.981175] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p < 0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p < 0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABL1 mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.
Collapse
Affiliation(s)
- Jaspal Kaeda
- Charité, Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik m.S. Hämatologie und Onkologie , Berlin , Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Wong D, Winter O, Hartig C, Siebels S, Szyska M, Tiburzy B, Meng L, Kulkarni U, Fähnrich A, Bommert K, Bargou R, Berek C, Chu VT, Bogen B, Jundt F, Manz RA. Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. PLoS One 2014; 9:e109018. [PMID: 25272036 PMCID: PMC4182881 DOI: 10.1371/journal.pone.0109018] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Accepted: 08/27/2014] [Indexed: 01/09/2023] Open
Abstract
Multiple myeloma is a bone marrow plasma cell tumor which is supported by the external growth factors APRIL and IL-6, among others. Recently, we identified eosinophils and megakaryocytes to be functional components of the micro-environmental niches of benign bone marrow plasma cells and to be important local sources of these cytokines. Here, we investigated whether eosinophils and megakaryocytes also support the growth of tumor plasma cells in the MOPC315.BM model for multiple myeloma. As it was shown for benign plasma cells and multiple myeloma cells, IL-6 and APRIL also supported MOPC315.BM cell growth in vitro, IL-5 had no effect. Depletion of eosinophils in vivo by IL-5 blockade led to a reduction of the early myeloma load. Consistent with this, myeloma growth in early stages was retarded in eosinophil-deficient ΔdblGATA-1 mice. Late myeloma stages were unaffected, possibly due to megakaryocytes compensating for the loss of eosinophils, since megakaryocytes were found to be in contact with myeloma cells in vivo and supported myeloma growth in vitro. We conclude that eosinophils and megakaryocytes in the niches for benign bone marrow plasma cells support the growth of malignant plasma cells. Further investigations are required to test whether perturbation of these niches represents a potential strategy for the treatment of multiple myeloma.
Collapse
Affiliation(s)
- David Wong
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
| | - Oliver Winter
- Charité - University Medicine Berlin, Department of Rheumatology and German Arthritis Research Center DRFZ, Berlin, Germany
| | - Christina Hartig
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
| | - Svenja Siebels
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
| | - Martin Szyska
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
| | - Benjamin Tiburzy
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
| | - Lingzhang Meng
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
| | - Upasana Kulkarni
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
| | - Anke Fähnrich
- University of Lübeck, Institute for Anatomy, Lübeck, Germany
| | - Kurt Bommert
- Comprehensive Cancer Centre Mainfranken, University Hospital Würzburg, Würzburg, Germany
| | - Ralf Bargou
- Department of Internal Medicine II, Division of Haematology and Medical Oncology, University Hospital Würzburg, Würzburg, Germany
| | - Claudia Berek
- German Arthritis Research Center (DRFZ Berlin), Berlin, Germany
| | - Van Trung Chu
- German Arthritis Research Center (DRFZ Berlin), Berlin, Germany
| | - Bjarne Bogen
- Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Franziska Jundt
- Department of Internal Medicine II, Division of Haematology and Medical Oncology, University Hospital Würzburg, Würzburg, Germany
| | - Rudolf Armin Manz
- University of Lübeck, Institute for Systemic Inflammation Research, ISEF, Lübeck, Germany
- * E-mail:
| |
Collapse
|
14
|
Schwarzer R, Nickel N, Godau J, Willie BM, Duda GN, Schwarzer R, Cirovic B, Leutz A, Manz R, Bogen B, Dörken B, Jundt F. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J 2014; 4:e217. [PMID: 24927406 PMCID: PMC4080208 DOI: 10.1038/bcj.2014.37] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2014] [Accepted: 04/30/2014] [Indexed: 01/16/2023] Open
Abstract
Despite evidence that deregulated Notch signalling is a master regulator of multiple myeloma (MM) pathogenesis, its contribution to myeloma bone disease remains to be resolved. Notch promotes survival of human MM cells and triggers human osteoclast activity in vitro. Here, we show that inhibition of Notch through the γ-secretase inhibitor XII (GSI XII) induces apoptosis of murine MOPC315.BM myeloma cells with high Notch activity. GSI XII impairs murine osteoclast differentiation of receptor activator of NF-κB ligand (RANKL)-stimulated RAW264.7 cells in vitro. In the murine MOPC315.BM myeloma model GSI XII has potent anti-MM activity and reduces osteolytic lesions as evidenced by diminished myeloma-specific monoclonal immunoglobulin (Ig)-A serum levels and quantitative assessment of bone structure changes via high-resolution microcomputed tomography scans. Thus, we suggest that Notch inhibition through GSI XII controls myeloma bone disease mainly by targeting Notch in MM cells and possibly in osteoclasts in their microenvironment. We conclude that Notch inhibition is a valid therapeutic strategy in MM.
Collapse
Affiliation(s)
- R Schwarzer
- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - N Nickel
- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - J Godau
- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - B M Willie
- Julius Wolff Institute and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - G N Duda
- Julius Wolff Institute and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - R Schwarzer
- Institute of Biology and Molecular Biophysics, Humboldt University Berlin, Berlin, Germany
| | - B Cirovic
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - A Leutz
- Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - R Manz
- Institute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany
| | - B Bogen
- 1] Centre for Immune Regulation, Institute of Immunology, Oslo University Hospital, Oslo, Norway [2] Jebsen Centre for Research on Influenza Vaccines, University of Oslo, Oslo, Norway
| | - B Dörken
- 1] Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany [2] Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - F Jundt
- 1] Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany [2] Department of Internal Medicine II, University Hospital Würzburg, University of Würzburg, Würzburg, Germany
| |
Collapse
|
15
|
Dimitrova L, Seitz V, Hecht J, Lenze D, Hansen P, Szczepanowski M, Ma L, Oker E, Sommerfeld A, Jundt F, Klapper W, Hummel M. PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma. Leukemia 2013; 28:213-6. [PMID: 23842424 DOI: 10.1038/leu.2013.211] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- L Dimitrova
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - V Seitz
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - J Hecht
- Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - D Lenze
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - P Hansen
- 1] Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany [2] Institute for Medical Genetics and Human Genetics, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - M Szczepanowski
- Institute of Pathology, Kiel University (CAU), Kiel, Germany
| | - L Ma
- 1] Institute of Pathology, Kiel University (CAU), Kiel, Germany [2] Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China
| | - E Oker
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - A Sommerfeld
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - F Jundt
- Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
| | - W Klapper
- Institute of Pathology, Kiel University (CAU), Kiel, Germany
| | - M Hummel
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| |
Collapse
|
16
|
Winter O, Dame C, Jundt F, Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol 2013; 189:5105-11. [PMID: 23169863 DOI: 10.4049/jimmunol.1202317] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Long-lived plasma cells survive in a protected microenvironment for years or even a lifetime and provide humoral memory by establishing persistent Ab titers. Long-lived autoreactive, malignant, and allergen-specific plasma cells are likewise protected in their survival niche and are refractory to immunosuppression, B cell depletion, and irradiation. Their elimination remains an essential therapeutic challenge. Recent data indicate that long-lived plasma cells reside in a multicomponent plasma cell niche with a stable mesenchymal and a dynamic hematopoietic component, both providing essential soluble and membrane-bound survival factors. Alternative niches with different hematopoietic cell components compensate fluctuations of single cell types but may also harbor distinct plasma cell subsets. In this Brief Review, we discuss conventional therapies in autoimmunity and multiple myeloma in comparison with novel drugs that target plasma cells and their niches. In the future, such strategies may enable the specific depletion of pathogenic plasma cells while leaving the protective humoral memory intact.
Collapse
Affiliation(s)
- Oliver Winter
- Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, 10117 Berlin, Germany.
| | | | | | | |
Collapse
|
17
|
Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H, Schwarzer R, Schünemann N, Jundt F, Lindeberg MM, Bogen B. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One 2012; 7:e51892. [PMID: 23284805 PMCID: PMC3527494 DOI: 10.1371/journal.pone.0051892] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2012] [Accepted: 11/07/2012] [Indexed: 01/03/2023] Open
Abstract
Multiple myeloma (MM) is a lethal human cancer characterized by a clonal expansion of malignant plasma cells in bone marrow. Mouse models of human MM are technically challenging and do not always recapitulate human disease. Therefore, new mouse models for MM are needed. Mineral-oil induced plasmacytomas (MOPC) develop in the peritoneal cavity of oil-injected BALB/c mice. However, MOPC typically grow extramedullary and are considered poor models of human MM. Here we describe an in vivo-selected MOPC315 variant, called MOPC315.BM, which can be maintained in vitro. When injected i.v. into BALB/c mice, MOPC315.BM cells exhibit tropism for bone marrow. As few as 10(4) MOPC315.BM cells injected i.v. induced paraplegia, a sign of spinal cord compression, in all mice within 3-4 weeks. MOPC315.BM cells were stably transfected with either firefly luciferase (MOPC315.BM.Luc) or DsRed (MOPC315.BM.DsRed) for studies using noninvasive imaging. MOPC315.BM.Luc cells were detected in the tibiofemoral region already 1 hour after i.v. injection. Bone foci developed progressively, and as of day 5, MM cells were detected in multiple sites in the axial skeleton. Additionally, the spleen (a hematopoietic organ in the mouse) was invariably affected. Luminescent signals correlated with serum myeloma protein concentration, allowing for easy tracking of tumor load with noninvasive imaging. Affected mice developed osteolytic lesions. The MOPC315.BM model employs a common strain of immunocompetent mice (BALB/c) and replicates many characteristics of human MM. The model should be suitable for studies of bone marrow tropism, development of osteolytic lesions, drug testing, and immunotherapy in MM.
Collapse
Affiliation(s)
- Peter O. Hofgaard
- Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Henriette C. Jodal
- Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Kurt Bommert
- Comprehensive Cancer Centre Mainfranken and Department of Internal Medicine II, Division of Haematology and Medical Oncology, University Hospital Würzburg, Würzburg, Germany
| | - Bertrand Huard
- Division of Hematology, University Hospitals of Geneva and Department of Pathology-Immunology, Geneva University Medical Centre, Geneva, Switzerland
| | - Jo Caers
- Department of Hematology, University of Liège, Liège, Belgium
| | - Harald Carlsen
- Institute for Nutrition Research, University of Oslo, Oslo, Norway
| | - Rolf Schwarzer
- Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Campus Virchow Clinic, Molekulares Krebsforschungszentrum, Berlin, Germany
| | - Nicole Schünemann
- Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Campus Virchow Clinic, Molekulares Krebsforschungszentrum, Berlin, Germany
| | - Franziska Jundt
- Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Campus Virchow Clinic, Molekulares Krebsforschungszentrum, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Mona M. Lindeberg
- Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
| | - Bjarne Bogen
- Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
- * E-mail:
| |
Collapse
|
18
|
Schwarzer R, Jundt F. Notch and NF-κB signaling pathways in the biology of classical Hodgkin lymphoma. Curr Mol Med 2011; 11:236-45. [PMID: 21375490 DOI: 10.2174/156652411795243423] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2010] [Accepted: 01/26/2011] [Indexed: 11/22/2022]
Abstract
Classical Hodgkin lymphoma (cHL) is now recognized as a B-cell-derived lymphoma which is characterized by only about 1% malignant pathognomonic Hodgkin and Reed-Sternberg (HRS) cells and an abundant infiltrate of reactive bystander cells. HRS cells are unique with respect to their lost B-cell-specific gene expression pattern and recurrent genetic lesions. Aberrant activity of Notch signaling, a highly conserved developmental pathway, acts as a negative regulator of the B cell program in HRS cells and thereby contributes to their reprogramming. Another striking feature and the major pathogenetic mechanism in HRS cells is constitutive NF-κB activation. A number of aberrations that contribute to canonical NF-κB activity in HRS cells have been described such as genetic lesions, deregulated receptor signaling and Epstein-Barr virus (EBV) infection. The importance of Notch and NF-κB signaling for cHL pathogenesis, their potential cross-talk and implications for future therapeutic applications are being discussed.
Collapse
Affiliation(s)
- R Schwarzer
- Department of Hematology and Oncology, Charité, Campus Virchow-Klinikum, University Medicine Berlin, 13353 Berlin, Germany
| | | |
Collapse
|
19
|
Mielke N, Schwarzer R, Calkhoven CF, Kaufman RJ, Dörken B, Leutz A, Jundt F. Eukaryotic initiation factor 2alpha phosphorylation is required for B-cell maturation and function in mice. Haematologica 2011; 96:1261-8. [PMID: 21565905 DOI: 10.3324/haematol.2011.042853] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND The control of translation initiation is a crucial component in the regulation of gene expression. The eukaryotic initiation factor 2α (eIF2α) mediates binding of the initiator transfer-messenger-RNA to the AUG initiation codon, and thus controls a rate-limiting step in translation initiation. Phosphorylation of eIF2α at serine 51 is linked to cellular stress response and attenuates translation initiation. The biochemistry of translation inhibition mediated by eIF2α phosphorylation is well characterized, yet the physiological importance in hematopoiesis remains only partially known. DESIGN AND METHODS Using hematopoietic stem cells carrying a non-phosphorylatable mutant form of eIF2α (eIF2αAA), we examined the efficiency of reconstitution in wild-type and B-cell-deficient microMT C57BL/6 recipients in two independent models. RESULTS We provide evidence that phosphorylation-deficient eIF2α mutant hematopoietic stem cells may repopulate lethally irradiated mice but have a defect in the development and maintenance of newly formed B cells in the bone marrow and of naïve follicular B cells in the periphery. The mature B-cell compartment is markedly reduced in bone marrow, spleen and peripheral blood, and B-cell receptor-mediated proliferation in vitro and serum immunoglobulin secretion in vivo are impaired. CONCLUSIONS The data suggest that regulation of translation through eIF2α phosphorylation is dispensable in hematopoietic reconstitution but essential during late B-cell development.
Collapse
Affiliation(s)
- Nina Mielke
- Department of Hematology and Oncology, Charité, Campus Virchow-Klinikum, University Medicine Berlin, Berlin, Germany
| | | | | | | | | | | | | |
Collapse
|
20
|
Köchert K, Ullrich K, Kreher S, Aster JC, Kitagawa M, Jöhrens K, Anagnostopoulos I, Jundt F, Lamprecht B, Zimber-Strobl U, Stein H, Janz M, Dörken B, Mathas S. High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas. Oncogene 2010; 30:1831-40. [DOI: 10.1038/onc.2010.544] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
21
|
Ellinghaus U, Rupec RA, Pabst O, Ignatius R, Förster R, Dörken B, Jundt F. IkappaBalpha is required for marginal zone B cell lineage development. Eur J Immunol 2008; 38:2096-105. [PMID: 18604869 DOI: 10.1002/eji.200838254] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Inactivation of members of the nuclear factor-kappaB (NF-kappaB) family results in the decrease or defect of marginal zone B (MZB) cells. It is not known which inhibitors of the NF-kappaB family (IkappaB) are required for MZB cell development. Here, we show that mice with B cell-specific inactivation of the main NF-kappaB inhibitor IkappaBalpha have a marked decrease of MZB cells and their presumed precursors. They exhibited increased mortality rates after blood-borne bacterial infection, indicating the importance of MZB cells for bacterial clearance. In contrast, response to T cell-dependent and -independent antigens resulted only in minor changes in immunoglobulin production. Our data demonstrate the importance of the intact NF-kappaB/IkappaBalpha pathway for proper MZB cell development.
Collapse
Affiliation(s)
- Ursula Ellinghaus
- Department of Hematology and Oncology, Charité, Campus Virchow-Klinikum, University Medicine Berlin, Berlin, Germany
| | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Aberrant Notch activation is linked to cancer since 1991 when mammalian Notch1 was first identified as part of the translocation t(7;9) in a subset of human T-cell acute lymphoblastic leukemias (T-ALL). Since then oncogenic Notch signaling has been found in many solid and hematopoietic neoplasms. Depending on tumor type Notch interferes with differentiation, proliferation, survival, cell-cycle progression, angiogenesis, and possibly self-renewal. In hematopoietic neoplasms, recent findings indicate an important role of Notch for T-ALL induction and progression and the pathogenesis of human T- and B-cell-derived lymphomas. Notch signaling has been identified as a potential new therapeutic target in these hematopoietic neoplasms. This review will focus on the most recent findings on Notch signaling in leukemias and lymphomas and its potential role in the maintenance of malignant stem cells.
Collapse
Affiliation(s)
- Franziska Jundt
- Department of Hematology and Oncology, Charité, Campus Virchow-Klinikum, University Medicine Berlin, 13353 Berlin, Germany.
| | | | | |
Collapse
|
23
|
Lietz A, Janz M, Sigvardsson M, Jundt F, Dörken B, Mathas S. Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis. Br J Haematol 2007; 137:342-8. [PMID: 17456056 DOI: 10.1111/j.1365-2141.2007.06583.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Similar to classical Hodgkin lymphoma (HL) tumour cells, primary effusion lymphoma (PEL) originates from mature B cells but displays a non-B cell phenotype, the mechanisms and consequences of which are not yet understood. This study showed that PEL lacked DNA binding activity of the B cell-determining transcription factors E2A, EBF and Pax5. PEL overexpressed the E2A antagonists ABF-1 and Id2, which have been described to block the B-cell differentiation program in classical HL. However, in contrast to HL cells, B lineage-inappropriate genes were not similarly upregulated in PEL, and reconstitution of B cell-specific E2A homodimer activity in PEL induced apoptosis. These data demonstrate that lineage infidelity in PEL is not as pronounced as in HL, and that the loss of the B cell-specific transcription factor E2A in PEL is implicated in apoptosis protection.
Collapse
Affiliation(s)
- Andreas Lietz
- Max-Delbrück-Centre for Molecular Medicine, Berlin and Haematology, Oncology and Tumorimmunology, Chartié, Medical University Berlin, Berlin, Germany
| | | | | | | | | | | |
Collapse
|
24
|
Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, Anagnostopoulos I, Lietz A, Sigvardsson M, Jundt F, Jöhrens K, Bommert K, Stein H, Dörken B. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2005; 7:207-15. [PMID: 16369535 DOI: 10.1038/ni1285] [Citation(s) in RCA: 132] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2005] [Accepted: 10/26/2005] [Indexed: 01/09/2023]
Abstract
B cell differentiation is controlled by a complex network of lineage-restricted transcription factors. How perturbations to this network alter B cell fate remains poorly understood. Here we show that classical Hodgkin lymphoma tumor cells, which originate from mature B cells, have lost the B cell phenotype as a result of aberrant expression of transcriptional regulators. The B cell-specific transcription factor program was disrupted by overexpression of the helix-loop-helix proteins ABF-1 and Id2. Both factors antagonized the function of the B cell-determining transcription factor E2A. As a result, expression of genes specific to B cells was lost and expression of genes not normally associated with the B lineage was upregulated. These data demonstrate the plasticity of mature human lymphoid cells and offer an explanation for the unique classical Hodgkin lymphoma phenotype.
Collapse
Affiliation(s)
- Stephan Mathas
- Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Mathas S, Jöhrens K, Joos S, Lietz A, Hummel F, Janz M, Jundt F, Anagnostopoulos I, Bommert K, Lichter P, Stein H, Scheidereit C, Dörken B. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005; 106:4287-93. [PMID: 16123212 DOI: 10.1182/blood-2004-09-3620] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Transcription factor nuclear factor kappa B (NF-kappaB) plays a central role in the pathogenesis of classical Hodgkin lymphoma (cHL). In anaplastic large-cell lymphomas (ALCLs), which share molecular lesions with cHL, the NF-kappaB system has not been equivalently investigated. Here we describe constitutive NF-kappaB p50 homodimer [(p50)2] activity in ALCL cells in the absence of constitutive activation of the IkappaB kinase (IKK) complex. Furthermore, (p50)2 contributes to the NF-kappaB activity in Hodgkin/Reed-Sternberg (HRS) cells. Bcl-3, which is an inducer of nuclear (p50)2 and is associated with (p50)2 in ALCL and HRS cell lines, is abundantly expressed in ALCL and HRS cells. Notably, a selective overexpression of Bcl-3 target genes is found in ALCL cells. By immunohistochemical screening of 288 lymphoma cases, a strong Bcl-3 expression in cHL and in peripheral T-cell non-Hodgkin lymphoma (T-NHL) including ALCL was found. In 3 of 6 HRS cell lines and 25% of primary ALCL, a copy number increase of the BCL3 gene locus was identified. Together, these data suggest that elevated Bcl-3 expression has an important function in cHL and peripheral T-NHL, in particular ALCL.
Collapse
Affiliation(s)
- Stephan Mathas
- Max-Delbrück-Center for Molecular Medicine, FG Dörken, D-13125 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Jundt F, Raetzel N, Müller C, Calkhoven CF, Kley K, Mathas S, Lietz A, Leutz A, Dörken B. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106:1801-7. [PMID: 15886325 DOI: 10.1182/blood-2004-11-4513] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The immunosuppressive macrolide rapamycin and its derivative everolimus (SDZ RAD, RAD) inhibit the mammalian target of rapamycin (mTOR) signaling pathway. In this study, we provide evidence that RAD has profound antiproliferative activity in vitro and in NOD/SCID mice in vivo against Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) cells. Moreover, we identified 2 molecular mechanisms that showed how RAD exerts antiproliferative effects in HL and ALCL cells. RAD down-regulated the truncated isoform of the transcription factor CCAAT enhancer binding protein beta (C/EBPbeta), which is known to disrupt terminal differentiation and induce a transformed phenotype. Furthermore, RAD inhibited constitutive nuclear factor kappaB (NF-kappaB) activity, which is a critical survival factor of HL cells. Pharmacologic inhibition of the mTOR pathway by RAD therefore interferes with essential proliferation and survival pathways in HL and ALCL cells and might serve as a novel treatment option.
Collapse
Affiliation(s)
- Franziska Jundt
- Charité, Campus Virchow-Klinikum, University Medicine Berlin, Augustenburger Platz 1, D-13 353 Berlin, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Sheetz RA, Staszel P, Tveter TS, Videaek F, Wada R, Yin Z, Zgura IS. Charged meson rapidity distributions in central Au+Au collisions at square root(sNN) = 200 GeV. Phys Rev Lett 2005; 94:162301. [PMID: 15904216 DOI: 10.1103/physrevlett.94.162301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2004] [Indexed: 05/02/2023]
Abstract
We have measured rapidity densities dN/dy of pi+/- and K+/- over a broad rapidity range (-0.1 < y < 3.5) for central Au + Au collisions at square root(sNN) = 200 GeV. These data have significant implications for the chemistry and dynamics of the dense system that is initially created in the collisions. The full phase-space yields are 1660 +/- 15 +/- 133 (pi+), 1683 +/- 16 +/- 135 (pi-), 286 +/- 5 +/- 23 (K+), and 242 +/- 4 +/- 19 (K-). The systematics of the strange to nonstrange meson ratios are found to track the variation of the baryochemical potential with rapidity and energy. Landau-Carruthers hydrodynamics is found to describe the bulk transport of the pions in the longitudinal direction.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Rupec RA, Jundt F, Rebholz B, Eckelt B, Weindl G, Herzinger T, Flaig MJ, Moosmann S, Plewig G, Dörken B, Förster I, Huss R, Pfeffer K. Stroma-Mediated Dysregulation of Myelopoiesis in Mice Lacking IκBα. Immunity 2005; 22:479-91. [PMID: 15845452 DOI: 10.1016/j.immuni.2005.02.009] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2004] [Revised: 02/15/2005] [Accepted: 02/23/2005] [Indexed: 01/02/2023]
Abstract
Hematopoiesis occurs in the liver and the bone marrow (BM) during murine development. Newborn mice with a ubiquitous deletion of I kappa B alpha develop a severe hematological disorder characterized by an increase of granulocyte/erythroid/monocyte/macrophage colony-forming units (CFU-GEMM) and hypergranulopoiesis. Here, we report that this particular myeloproliferative disturbance is mediated by continuously deregulated perinatal expression of Jagged1 in I kappa B alpha-deficient hepatocytes. The result is a permanent activation of Notch1 in neutrophils. In contrast, in mice with a conditional deletion of I kappa B alpha only in the myeloid lineage (ikba(flox/flox) x LysM-Cre) and in fetal liver cell chimeras (ikba(FL delta/FL delta)), a cell-autonomous induction of the myeloproliferative disease was not observed. Coculture of I kappa B alpha-deficient hepatocytes with wild-type (wt) BM cells induced a Jagged1-dependent increase in CFUs. In summary, we show that cell-fate decisions leading to a premalignant hematopoietic disorder can be initiated by nonhematopoietic cells with inactive I kappa B alpha.
Collapse
Affiliation(s)
- Rudolf A Rupec
- Department of Dermatology, University of Munich, Frauenlobstrasse 9-11, D-80337 Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Arsene I, Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Ito H, Jipa A, Jørdre JI, Jundt F, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Lindal S, Lystad R, Løvhøiden G, Majka Z, Makeev A, Mikelsen M, Murray M, Natowitz J, Neumann B, Nielsen BS, Ouerdane D, Płaneta R, Rami F, Ristea C, Ristea O, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Sheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Yin Z, Zgura IS. Centrality dependence of charged-particle pseudorapidity distributions from d + Au collisions at sqrt[sNN] = 200 GeV. Phys Rev Lett 2005; 94:032301. [PMID: 15698255 DOI: 10.1103/physrevlett.94.032301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2004] [Indexed: 05/24/2023]
Abstract
Charged-particle pseudorapidity densities are presented for the d + Au reaction at sqrt[s(NN)] = 200 GeV with -4.2 < or = eta < or = 4.2. The results, from the BRAHMS experiment at BNL Relativistic Heavy-Ion Collider, are shown for minimum-bias events and 0%-30%, 30%-60%, and 60%-80% centrality classes. Models incorporating both soft physics and hard, perturbative QCD-based scattering physics agree well with the experimental results. The data do not support predictions based on strong-coupling, semiclassical QCD. In the deuteron-fragmentation region the central 200 GeV data show behavior similar to full-overlap d+Au results at sqrt[s(NN)] = 19.4 GeV.
Collapse
Affiliation(s)
- I Arsene
- University of Bucharest, Bucharest, Romania
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Arsene I, Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Lindal S, Lystad R, Løvhøiden G, Majka Z, Makeev A, Mikelsen M, Murray M, Natowitz J, Neumann B, Nielsen BS, Ouerdane D, Płaneta R, Rami F, Ristea C, Ristea O, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Scheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Yin Z, Zgura IS. Evolution of the nuclear modification factors with rapidity and centrality in d + Au collisions at (sqrt)[N(S)N]=200 GeV. Phys Rev Lett 2004; 93:242303. [PMID: 15697798 DOI: 10.1103/physrevlett.93.242303] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2004] [Revised: 08/27/2004] [Indexed: 05/24/2023]
Abstract
We report on a study of the transverse momentum dependence of nuclear modification factors R(dAu) for charged hadrons produced in deuteron + gold collisions at sqrt[s(NN)]=200 GeV, as a function of collision centrality and of the pseudorapidity (eta=0, 1, 2.2, 3.2) of the produced hadrons. We find a significant and systematic decrease of R(dAu) with increasing rapidity. The midrapidity enhancement and the forward rapidity suppression are more pronounced in central collisions relative to peripheral collisions. These results are relevant to the study of the possible onset of gluon saturation at energies reached at BNL RHIC.
Collapse
Affiliation(s)
- I Arsene
- Brookhaven National Laboratory, Upton, NY 11973, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Scheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Yin Z, Zgura IS. Nuclear stopping in Au+Au collisions at square root of S(NN)=200 GeV. Phys Rev Lett 2004; 93:102301. [PMID: 15447397 DOI: 10.1103/physrevlett.93.102301] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2003] [Indexed: 05/24/2023]
Abstract
Transverse momentum spectra and rapidity densities, dN/dy, of protons, antiprotons, and net protons (p-p) from central (0%-5%) Au+Au collisions at square root of S(NN)=200 GeV were measured with the BRAHMS experiment within the rapidity range 0</=y</=3. The proton and antiproton dN/dy decrease from midrapidity to y=3. The net-proton yield is roughly constant for y<1 at dN/dy approximately 7, and increases to dN/dy approximately 12 at y approximately 3. The data show that collisions at this energy exhibit a high degree of transparency and that the linear scaling of rapidity loss with rapidity observed at lower energies is broken. The energy loss per participant nucleon is estimated to be 73+/-6 GeV.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, Blegdamsvej 17, University of Copenhagen, Copenhagen 2100, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Jundt F, Lempert T, Dörken B, Pezzutto A. Trimethoprim-Sulfamethoxazole Exacerbates Posthypoxic Action Myoclonus in a Patient with Suspicion of Pneumocystis jiroveci Infection. Infection 2004; 32:176-8. [PMID: 15188079 DOI: 10.1007/s15010-004-3011-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2003] [Accepted: 07/28/2003] [Indexed: 10/26/2022]
Abstract
We describe a 58-year-old patient with relapsing high-grade non-Hodgkin's lymphoma who exhibited exacerbation of posthypoxic action myoclonus during high-dose intravenous trimethoprim-sulfamethoxazole (TMP-SMX) treatment for highly suspicious Pneumocystis jiroveci pneumonia (PCP). Three months previously the patient had experienced a hypoxic insult caused by respiratory arrest due to an anaphylactic reaction to antibiotic therapy. He had developed posthypoxic action myoclonus (Lance-Adams syndrome), which was well controlled by oral treatment with piracetam. However, after TMP-SMX therapy (115 mg/kg daily) was started for suspicion of newly developed PCP, posthypoxic action myoclonus worsened dramatically resulting in complete disability. Anti-myoclonic therapy with increased doses of piracetam and valproic acid did not significantly improve his clinical condition. Only when TMPSMX doses were reduced (38 mg/kg daily) on day 12 did action myoclonus cease within 2 to 3 days. We suggest that TMP-SMX can exacerbate posthypoxic action myoclonus.
Collapse
Affiliation(s)
- F Jundt
- Dept. of Hematology and Oncology, Charité, Campus Virchow-Klinikum, Humboldt University of Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany.
| | | | | | | |
Collapse
|
33
|
Jundt F, Pröbsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S, Bargou RC, Manz R, Stein H, Dörken B. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103:3511-5. [PMID: 14726396 DOI: 10.1182/blood-2003-07-2254] [Citation(s) in RCA: 159] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Abstract
Notch receptors expressed on hematopoietic stem cells interact with their ligands on bone marrow stromal cells and thereby control cell fate decisions and survival. We recently demonstrated that Notch signaling is involved in proliferation and survival of B cell-derived tumor cells of classic Hodgkin disease and described a novel mechanism for the oncogenic capacity of Notch. In this study we investigated whether Notch signaling is involved in the tight interactions between neoplastic plasma cells and their bone marrow microenvironment, which are essential for tumor cell growth in multiple myeloma (MM). Here we demonstrate that Notch receptors and their ligand Jagged1 are highly expressed in cultured and primary MM cells, whereas nonneoplastic counterparts show low to undetectable levels of Notch. Functional data indicate that ligand-induced Notch signaling is a growth factor for MM cells and suggest that these interactions contribute to myelomagenesis in vivo. (Blood. 2004;103:3511-3515)
Collapse
Affiliation(s)
- Franziska Jundt
- Department of Hematology and Oncology, Charité, Campus Virchow-Klinikum, University Medicine Berlin, Berlin, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M, Jundt F, Hirsch B, Jöhrens-Leder K, Vornlocher HP, Bommert K, Stein H, Dörken B. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. ACTA ACUST UNITED AC 2004; 199:1041-52. [PMID: 15078899 PMCID: PMC2211891 DOI: 10.1084/jem.20031080] [Citation(s) in RCA: 139] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Resistance to death receptor–mediated apoptosis is supposed to be important for the deregulated growth of B cell lymphoma. Hodgkin/Reed-Sternberg (HRS) cells, the malignant cells of classical Hodgkin's lymphoma (cHL), resist CD95-induced apoptosis. Therefore, we analyzed death receptor signaling, in particular the CD95 pathway, in these cells. High level CD95 expression allowed a rapid formation of the death-inducing signaling complex (DISC) containing Fas-associated death domain–containing protein (FADD), caspase-8, caspase-10, and most importantly, cellular FADD-like interleukin 1β–converting enzyme-inhibitory protein (c-FLIP). The immunohistochemical analysis of the DISC members revealed a strong expression of CD95 and c-FLIP overexpression in 55 out of 59 cases of cHL. FADD overexpression was detectable in several cases. Triggering of the CD95 pathway in HRS cells is indicated by the presence of CD95L in cells surrounding them as well as confocal microscopy showing c-FLIP predominantly localized at the cell membrane. Elevated c-FLIP expression in HRS cells depends on nuclear factor (NF)-κB. Despite expression of other NF-κB–dependent antiapoptotic proteins, the selective down-regulation of c-FLIP by small interfering RNA oligoribonucleotides was sufficient to sensitize HRS cells to CD95 and tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis. Therefore, c-FLIP is a key regulator of death receptor resistance in HRS cells.
Collapse
Affiliation(s)
- Stephan Mathas
- Max-Delbrück-Center for Molecular Medicine, FG Dörken, D-13125 Berlin, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Loddenkemper C, Anagnostopoulos I, Hummel M, Jöhrens-Leder K, Foss HD, Jundt F, Wirth T, Dörken B, Stein H. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004; 202:60-9. [PMID: 14694522 DOI: 10.1002/path.1485] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
It has previously been demonstrated that in cultured and in situ tumour cells of classical Hodgkin lymphoma (cHL), the immunoglobulin (Ig) promoter is inactive and its transcription factors Oct2 and/or BOB.1/OBF.1 are down-regulated. In this study, the analysis of these transcription factors has been extended to a broad spectrum of B-cell malignancies and the findings have been related to the situation in normal B-cells of various differentiation stages and to the expression of Ig. Furthermore, an additional Ig transcription factor, PU.1, recently described to be absent from cHL, and a further regulatory element of the Ig gene, the intronic Emu enhancer, have been studied. BOB.1/OBF.1 and Oct2 were present in all B-cells expressing Ig, whereas PU.1 proved to be absent from late B-cell differentiation stages and from a subset of germinal centre B-cells. Interestingly, there were several normal (eg germinal centre centroblasts and monocytoid B-cells) and malignant B-cell populations (eg a proportion of diffuse large B-cell lymphomas, DLBCLs) that were Ig-negative, despite their BOB.1/OBF.1 and Oct2 expression. This study further shows that absence of PU.1 alone, as well as inactivation of the intronic Emu enhancer, is not sufficient to down-regulate Ig transcription. Taken together, the simultaneous absence of PU.1, Oct2, and/or BOB.1/OBF.1 is unique to Hodgkin and Reed-Sternberg (HRS) cells and cannot be detected in normal B-cell subsets or B-cell non-Hodgkin lymphomas (B-NHLs). This supports the concept that the down-regulation of Ig in cHL does not reflect a physiological situation, but a defect probably closely linked to the pathogenesis of cHL.
Collapse
Affiliation(s)
- Christoph Loddenkemper
- Institute of Pathology, Consultation and Reference Centre for Lymph Node Pathology and Haematopathology, Benjamin Franklin University Hospital, Free University Berlin, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Arsene I, Bearden IG, Beavis D, Besliu C, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Ito H, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Lindal S, Lystad G, Løvhøiden G, Majka Z, Makeev A, McBreen B, Mikelsen M, Murray M, Natowitz J, Neumann B, Nielsen BS, Norris J, Ouerdane D, Płaneta R, Rami F, Ristea C, Ristea O, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Scheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Yin Z, Zgura IS. Transverse-momentum spectra in Au+Au and d+Au collisions at sqrt[s(NN)]=200 GeV and the pseudorapidity dependence of high-p(T) suppression. Phys Rev Lett 2003; 91:072305. [PMID: 12935010 DOI: 10.1103/physrevlett.91.072305] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2003] [Indexed: 05/24/2023]
Abstract
We present spectra of charged hadrons from Au+Au and d+Au collisions at sqrt[s(NN)]=200 GeV measured with the BRAHMS experiment at RHIC. The spectra for different collision centralities are compared to spectra from p+(-)p collisions at the same energy scaled by the number of binary collisions. The resulting ratios (nuclear modification factors) for central Au+Au collisions at eta=0 and eta=2.2 evidence a strong suppression in the high p(T) region (>2 GeV/c). In contrast, the d+Au nuclear modification factor (at eta=0) exhibits an enhancement of the high p(T) yields. These measurements indicate a high energy loss of the high p(T) particles in the medium created in the central Au+Au collisions. The lack of suppression in d+Au collisions makes it unlikely that initial state effects can explain the suppression in the central Au+Au collisions.
Collapse
Affiliation(s)
- I Arsene
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102:1028-34. [PMID: 12676792 DOI: 10.1182/blood-2002-04-1154] [Citation(s) in RCA: 133] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Arsenic can induce apoptosis and is an efficient drug for the treatment of acute promyelocytic leukemia. Currently, clinical studies are investigating arsenic as a therapeutic agent for a variety of malignancies. In this study, Hodgkin/Reed-Sternberg (HRS) cell lines served as model systems to characterize the role of nuclear factor-kappaB (NF-kappaB) in arsenic-induced apoptosis. Arsenic rapidly down-regulated constitutive IkappaB kinase (IKK) as well as NF-kappaB activity and induced apoptosis in HRS cell lines containing functional IkappaB proteins. In these cell lines, apoptosis was blocked by inhibition of caspase-8 and caspase-3-like activity. Furthermore, arsenic treatment down-regulated NF-kappaB target genes, including tumor necrosis factor-alphareceptor-associated factor 1 (TRAF1), c-IAP2, interleukin-13 (IL-13), and CCR7. In contrast, cell lines with mutated, functionally inactive IkappaB proteins or with a weak constitutive IKK/NF-kappaB activity showed no alteration of the NF-kappaB activity and were resistant to arsenic-induced apoptosis. A direct role of the NF-kappaB pathway in arsenic-induced apoptosis is shown by transient overexpression of NF-kappaB-p65 in L540Cy HRS cells, which protected the cells from arsenic-induced apoptosis. In addition, treatment of NOD/SCID mice with arsenic trioxide induced a dramatic reduction of xenotransplanted L540Cy Hodgkin tumors concomitant with NF-kappaB inhibition. We conclude that inhibition of NF-kappaB contributes to arsenic-induced apoptosis. Furthermore, pharmacologic inhibition of the IKK/NF-kappaB activity might be a powerful treatment option for Hodgkin lymphoma.
Collapse
Affiliation(s)
- Stephan Mathas
- Max-Delbrück-Center for Molecular Medicine, FG Dörken, Robert-Rössle-Str. 10, D-13125 Berlin, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Bearden IG, Beavis D, Besliu C, Blyakhman Y, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Germinario M, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jakobsen E, Jipa A, Jundt F, Jørdre JI, Jørgensen CE, Karabowicz R, Keutgen T, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, McBreen B, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Olness J, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Scheetz RA, Staszel P, Tveter TS, Videbaek F, Wada R, Wieloch A, Yin Z, Zgura IS. Rapidity dependence of charged antihadron to hadron ratios in Au+Au collisions at sqrt[s(NN)]=200 GeV. Phys Rev Lett 2003; 90:102301. [PMID: 12688991 DOI: 10.1103/physrevlett.90.102301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2002] [Indexed: 05/24/2023]
Abstract
We present ratios of the numbers of charged antihadrons to hadrons (pions, kaons, and protons) in Au+Au collisions at sqrt[s(NN)]=200 GeV as a function of rapidity in the range y=0-3. While the ratios at midrapidity are approaching unity, the K(-)/K(+) and p;/p ratios decrease significantly at forward rapidities. An interpretation of the results within the statistical model indicates a reduction of the baryon chemical potential from mu(B) approximately 130 MeV at y=3 to mu(B) approximately 25 MeV at y=0.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, Blegdamsvej 17, University of Copenhagen, Copenhagen 2100, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dörken B, Scheidereit C. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21:4104-13. [PMID: 12145210 PMCID: PMC126136 DOI: 10.1093/emboj/cdf389] [Citation(s) in RCA: 277] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AP-1 family transcription factors have been implicated in the control of proliferation, apoptosis and malignant transformation. However, their role in oncogenesis is unclear and no recurrent alterations of AP-1 activities have been described in human cancers. Here, we show that constitutively activated AP-1 with robust c-Jun and JunB overexpression is found in all tumor cells of patients with classical Hodgkin's disease. A similar AP-1 activation is present in anaplastic large cell lymphoma (ALCL), but is absent in other lymphoma types. Whereas c-Jun is up-regulated by an autoregulatory process, JunB is under control of NF-kappa B. Activated AP-1 supports proliferation of Hodgkin cells, while it suppresses apoptosis of ALCL cells. Furthermore, AP-1 cooperates with NF-kappa B and stimulates expression of the cell-cycle regulator cyclin D2, proto-oncogene c-met and the lymphocyte homing receptor CCR7, which are all strongly expressed in primary HRS cells. Together, these data suggest an important role of AP-1 in lymphoma pathogenesis.
Collapse
MESH Headings
- Cell Division
- Cell Transformation, Neoplastic/genetics
- Cyclin D2
- Cyclins/biosynthesis
- Cyclins/genetics
- DNA, Neoplasm/metabolism
- Gene Expression Regulation, Neoplastic/drug effects
- Gene Expression Regulation, Neoplastic/physiology
- Gene Expression Regulation, Neoplastic/radiation effects
- Genes, jun
- Hodgkin Disease/genetics
- Hodgkin Disease/pathology
- Humans
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Non-Hodgkin/genetics
- Lymphoma, Non-Hodgkin/pathology
- MAP Kinase Signaling System/drug effects
- MAP Kinase Signaling System/radiation effects
- Mitogens/pharmacology
- NF-kappa B/physiology
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Neoplasm Proteins/physiology
- Proto-Oncogene Mas
- Proto-Oncogene Proteins c-jun/biosynthesis
- Proto-Oncogene Proteins c-jun/genetics
- Proto-Oncogene Proteins c-jun/physiology
- Proto-Oncogene Proteins c-met/biosynthesis
- Proto-Oncogene Proteins c-met/genetics
- Receptors, CCR7
- Receptors, Chemokine/biosynthesis
- Receptors, Chemokine/genetics
- Recombinant Fusion Proteins/physiology
- Reed-Sternberg Cells/drug effects
- Reed-Sternberg Cells/metabolism
- Reed-Sternberg Cells/radiation effects
- Tetradecanoylphorbol Acetate/pharmacology
- Transcription Factor AP-1/genetics
- Transcription Factor AP-1/physiology
- Transcription, Genetic
- Transfection
- Tumor Cells, Cultured/drug effects
- Tumor Cells, Cultured/metabolism
- Tumor Cells, Cultured/radiation effects
- Ultraviolet Rays
Collapse
Affiliation(s)
- Stephan Mathas
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Michael Hinz
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Ioannis Anagnostopoulos
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Daniel Krappmann
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Andreas Lietz
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Franziska Jundt
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Kurt Bommert
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Fatima Mechta-Grigoriou
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Harald Stein
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Bernd Dörken
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| | - Claus Scheidereit
- Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Straße 10, D-13125 Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University, Lindenberger Weg 80, D-13125 Berlin, Institute for Pathology, Universitätsklinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany and Unité des Virus Oncogènes, URA CNRS 1644, Institut Pasteur, 28 Rue du Dr Roux, 75724 Paris cedex 15, France Corresponding author e-mail:
| |
Collapse
|
40
|
Bearden IG, Beavis D, Besliu C, Blyakhman Y, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Enger E, Gaardhøje JJ, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jakobsen E, Jipa A, Jørdre JI, Jundt F, Jørgensen CE, Karabowicz R, Keutgen T, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden G, Majka Z, Makeev A, McBreen B, Mikelsen M, Murray M, Natowitz J, Nielsen BS, Norris J, Olchanski K, Olness J, Ouerdane D, Płaneta R, Rami F, Ristea C, Röhrich D, Samset BH, Sandberg D, Sanders SJ, Sheetz RA, Staszel P, Thorsteinsen TF, Tveter TS, Videbaek F, Wada R, Wieloch A, Zgura IS. Pseudorapidity distributions of charged particles from Au + Au collisions at the maximum RHIC energy, square root[s(NN)] = 200 GeV. Phys Rev Lett 2002; 88:202301. [PMID: 12005556 DOI: 10.1103/physrevlett.88.202301] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2001] [Revised: 02/14/2002] [Indexed: 05/23/2023]
Abstract
We present charged-particle multiplicities as a function of pseudorapidity and collision centrality for the 197Au+197Au reaction at square root[s(NN)] = 200 GeV. For the 5% most central events we obtain dN(ch)/deta/(eta = 0) = 625+/-55 and N(ch)/(-4.7< or =eta < or =4.7) = 4630 +/- 370, i.e., 14% and 21% increases, respectively, relative to square root[s(NN)] = 130 GeV collisions. Charged-particle production per pair of participant nucleons is found to increase from peripheral to central collisions around midrapidity. These results constrain current models of particle production at the highest RHIC energy.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99:3398-403. [PMID: 11964309 DOI: 10.1182/blood.v99.9.3398] [Citation(s) in RCA: 311] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Notch signaling controls cell fate decisions of hematopoietic progenitors by inhibiting certain steps of differentiation and inducing either self-renewal or differentiation toward lymphoid or myeloid lineages. In addition, truncated Notch1 alleles could be associated with 10% of all cases of human T lymphoblastic leukemia and, when introduced into mouse bone marrow stem cells, cause T-cell neoplasms. However, functional links between the abundant expression of intact Notch1 and oncogenesis are still lacking. Here we show that Notch1 is highly expressed in B- and T-cell-derived tumor cells of Hodgkin and anaplastic large cell lymphoma. We demonstrate a novel mechanism for the oncogenic capacity of Notch1 by showing that the interaction between intact Notch1 on tumor cells and its ligand Jagged1 dramatically induces proliferation and inhibition of apoptosis in vitro. We further provide evidence that in Hodgkin and anaplastic large cell lymphoma, Jagged1 is expressed in malignant and in bystander cells colocalizing with Notch1-positive tumor cells. Notch1 signaling may therefore be activated in tumor cells by Jagged1 through homotypic or heterotypic cell-cell interactions, and it seems likely that these interactions contribute to lymphomagenesis in vivo. Thus, our data suggest that activated Notch1 signaling plays an important role in the pathobiology of Hodgkin and anaplastic large cell lymphoma and that it might be a potential new target for treatment.
Collapse
Affiliation(s)
- Franziska Jundt
- Charité, Robert-Rössle-Klinik, Humboldt University of Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
42
|
Jundt F, Kley K, Anagnostopoulos I, Schulze Pröbsting K, Greiner A, Mathas S, Scheidereit C, Wirth T, Stein H, Dörken B. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002; 99:3060-2. [PMID: 11929801 DOI: 10.1182/blood.v99.8.3060] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Immunoglobulin transcription is impaired in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin disease (cHD). We recently demonstrated that defective immunoglobulin promoter transcription correlates with the down-regulation of the B-cell transcription factors Oct2 and BOB.1/OBF.1. These results prompted us to investigate whether immunoglobulin enhancer activity is also impaired in HRS cells and whether as yet unidentified factors could be necessary for immunoglobulin enhancer activity in HRS cells of cHD. Here we analyzed 30 cases of cHD for expression of the Ets family member PU.1 that is known to collaborate with multiple transcription factors and to regulate expression of immunoglobulin genes. We show that PU.1 is not expressed in primary and cultured HRS cells. Reintroduction of PU.1 and Oct2 in cultured HRS cells restored the activity of cotransduced immunoglobulin enhancer constructs. Our study identifies PU.1 deficiency as a recurrent defect in HRS cells that might contribute to their impairment of immunoglobulin transcription.
Collapse
Affiliation(s)
- Franziska Jundt
- Charité, Robert-Rössle-Klinik, Humboldt University of Berlin, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002; 21:1485-92. [PMID: 11896576 DOI: 10.1038/sj.onc.1205211] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2001] [Revised: 11/19/2001] [Accepted: 11/28/2001] [Indexed: 11/08/2022]
Abstract
Sp1 binding sites have been identified in enhancer/promoter regions of several growth and cell cycle regulated genes, and it has been shown that Sp1 is increasingly phosphorylated in G1 phase of the cell cycle. Interactions of Sp1 with proteins involved in control of cell cycle and tumor formation have been reported. Here we show that expression of Sp1 protein predominates in the G1 phase of the cell cycle in epithelial cells. This is achieved by proteasome-dependent degradation. Inhibition of endogeneous Sp1 activity by a dominant-negative Sp1 mutant was associated with a cell cycle arrest in G1 phase, a strongly reduced expression of cyclin D1, the EGF-receptor and increased levels of p27Kip1. We have thus identified Sp1 as an important regulator of the cell cycle in G1 phase.
Collapse
Affiliation(s)
- Edgar Grinstein
- Institut für Transplantationsdiagnostik und Zelltherapeutika, Heinrich Heine Universität Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.
| | | | | | | | | |
Collapse
|
44
|
Bearden IG, Beavis D, Besliu C, Blyakhman Y, Brzychczyk J, Budick B, Bøggild H, Chasman C, Christensen CH, Christiansen P, Cibor J, Debbe R, Gaardhøje JJ, Grotowski K, Hagel K, Hansen O, Holm A, Holme AK, Ito H, Jakobsen E, Jipa A, Jørdre JI, Jundt F, Jørgensen CE, Keutgen T, Kim EJ, Kozik T, Larsen TM, Lee JH, Lee YK, Løvhøiden GL, Majka Z, Makeev A, McBreen B, Murray M, Natowitz J, Nielsen BS, Olchanski K, Olness J, Ouerdane D, Planeta R, Rami F, Röhrich D, Samset BH, Sanders SJ, Sheetz RA, Sosin Z, Staszel P, Thorsteinsen TF, Tveter TS, Videbaek F, Wada R, Wieloch A, Zgura IS. Rapidity dependence of antiproton-to-proton ratios in Au+Au collisions at square root of (sNN) = 130 GeV. Phys Rev Lett 2001; 87:112305. [PMID: 11531519 DOI: 10.1103/physrevlett.87.112305] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2001] [Indexed: 05/23/2023]
Abstract
Measurements, with the BRAHMS detector, of the antiproton-to-proton ratio at midrapidities and forward rapidities, are presented for Au+Au reactions at square root of [s(NN)] = 130 GeV, and for three different collision centralities. For collisions in the 0%-40% centrality range, we find N(&pmacr;)/N(p) = 0.64+/-0.04((stat))+/-0.06((syst)) at y approximately 0, 0.66+/-0.03+/-0.06 at y approximately 0.7, and 0.41+/-0.04+/-0.06 at y approximately 2. The ratios are found to be nearly independent of collision centrality and transverse momentum. The antiproton and proton rapidity densities vary differently with rapidity, and indicate a significant degree of collision transparency, although a net-baryon free midrapidity plateau (Bjorken limit) is not yet reached.
Collapse
Affiliation(s)
- I G Bearden
- Niels Bohr Institute, University of Copenhagen, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, Dörken B. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94:3129-34. [PMID: 10556199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
The transcription factor NF kappa B (NF-kappaB) mediates the expression of numerous genes involved in diverse functions such as inflammation, immune response, apoptosis, and cell proliferation. We recently identified constitutive activation of NF-kappaB (p50/p65) as a common feature of Hodgkin/Reed-Sternberg (HRS) cells preventing these cells from undergoing apoptosis and triggering proliferation. To examine possible alterations in the NF-kappaB/IkappaB system, which might be responsible for constitutive NF-kappaB activity, we have analyzed the inhibitor I kappa B alpha (IkappaBalpha) in primary and cultured HRS cells on protein, mRNA, and genomic levels. In lymph node biopsy samples from Hodgkin's disease patients, IkappaBalpha mRNA proved to be strongly overexpressed in the HRS cells. In 2 cell lines (L428 and KM-H2), we detected mutations in the IkappaBalpha gene, resulting in C-terminally truncated proteins, which are presumably not able to inhibit NF-kappaB-DNA binding activity. Furthermore, an analysis of the IkappaBalpha gene in single HRS cells micromanipulated from frozen tissue sections showed a monoallelic mutation in 1 of 10 patients coding for a comparable C-terminally truncated IkappaBalpha protein. We suggest that the observed IkappaBalpha mutations contribute to constitutive NF-kappaB activity in cultured and primary HRS cells and are therefore involved in the pathogenesis of these Hodgkin's disease (HD) patients. The demonstrated constitutive overexpression of IkappaBalpha in HRS cells evidences a deregulation of the NF-kappaB/IkappaB system also in the remaining cases, probably due to defects in other members of the IkappaB family.
Collapse
Affiliation(s)
- F Emmerich
- Humboldt University of Berlin, Universitätsklinikum Charité, Robert-Rössle-Klinik, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Müller G, Foss HD, Royer HD, Stein H, Dörken B. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94:2065-71. [PMID: 10477736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
Hodgkin's disease is histopathologically characterized by the relative scarcity of neoplastic Hodgkin and Reed-Sternberg cells and for yet unknown reasons by an abundant reactive background of T lymphocytes and often eosinophils. Eotaxin is a CC-chemokine attracting eosinophils and T helper 2 (Th2) cells in allergic inflammation. We now report that eotaxin is strongly expressed in fibroblasts of Hodgkin's disease tissues, whereas Hodgkin/Reed-Sternberg cells do not express this chemokine. In tissue culture, Hodgkin's disease tumor cells induce eotaxin expression in cocultured dermal fibroblasts in a concentration leading to a specific chemotactic response of a Th2 cell clone. Production of tumor necrosis factor-alpha (TNF-alpha) by Hodgkin/Reed-Sternberg cells appears to be responsible for this induction, because blocking of TNF-alpha by neutralizing antibodies prevented fibroblast eotaxin expression. Our data suggest that eotaxin is involved in the pathobiology of Hodgkin's disease by contributing to eosinophil and T-lymphocyte recruitment.
Collapse
Affiliation(s)
- F Jundt
- Universitätsklinikum Charité, Robert-Rössle-Klinik, Humboldt University of Berlin, Berlin, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Dzelalija M, Cindro N, Basrak Z, Caplar R, Hölbling S, Bini M, Maurenzig PR, Olmi A, Pasquali G, Poggi G, Taccetti N, Cerruti C, Coffin JP, Don R, Fintz P, Guillaume G, Houari A, Jundt F, Kuhn C, Rami F, Tezkratt R, Wagner P, Biegansky J, Kotte R, Mösner J, Neubert W, Wohlfarth D, Alard JP, Amouroux V, Bastid N, Berger L, Belayev IM, Boussange S, Buta A, Dupieux P, Erö J, Fodor Z, Fraysse L, Gobbi A, Herrmann N, Hildenbrand KD, Ibnouzahir M, Kecskemeti J, Koncz P, Korchagin Y, Krämer M, Lebedev A, Legrand I, Manko V, Mgebrishvili G, Moisa D, Montarou G, Montbel I, Pelte D, Petrovici M, Pras P, Ramillien V, Reisdorf W, Schüll D, Seres Z, Sikora B, Simion V, Smolyankin S, Sodan U. Entropy in central Au+Au reactions between 100 and 400A MeV. Phys Rev C Nucl Phys 1995; 52:346-355. [PMID: 9970514 DOI: 10.1103/physrevc.52.346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
48
|
Petrovici M, Herrmann N, Legrand I, Gobbi A, Hildenbrand KD, Reisdorf W, Buta A, Freifelder R, Jeong SC, Krämer M, Moisa D, Schüll D, Simion V, Sodan U, Teh K, Wessels JP, Wienold T, Alard JP, Amouroux V, Basrak Z, Bastid N, Belyaev IM, Berger L, Blaich T, Boussange S, Caplar R, Cerruti C, Cindro N, Coffin JP, Donà R, Dupieux P, Erö J, Fintz P, Fodor Z, Fraysse L, Guillaume G, Hölbling S, Houari A, Jundt F, Kecskemeti J, Koncz P, Korchagin Y, Kotte R, Kuhn C, Ibnouzahir M, Lebedev A, Maguire C, Manko V, Mösner J, Montarou G, Montbel I, Morel P, Neubert W, Pelte D, Rami F, Ramillien V, Sadchikov A, Seres Z, Sikora B, Smolyankin S, Tezkratt R, Trzaska M, Vasiliev MA, Wagner P. Cluster formation during expansion of hot and compressed nuclear matter produced in central collisions of Au on Au at 250A MeV. Phys Rev Lett 1995; 74:5001-5004. [PMID: 10058658 DOI: 10.1103/physrevlett.74.5001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
49
|
Kotte R, Kämpfer B, Mösner J, Neubert W, Wohlfarth D, Alard JP, Amouroux V, Basrak Z, Bastid N, Belayev IM, Berger L, Blaich T, Boussange S, Buta A, Caplar R, Cerruti C, Cindro N, Coffin JP, Don R, Dupieux P, Erö J, Fan ZG, Fintz P, Fodor Z, Fraysse L, Freifelder R, Frolov S, Gobbi A, Grigorian Y, Guillaume G, Herrmann N, Hildenbrand KD, Hölbling S, Houari O, Ibnouzahir M, Jeong SC, Jundt F, Kecskemeti J, Koncz P, Korchagin Y, Krämer M, Kuhn C, Legrand I, Lebedev A, Manko V, Matulewicz T, Mgebrishvili G, Moisa D, Montarou G, Montbel I, Pelte D, Petrovici M, Pras P, Rami F, Ramillien V, Reisdorf W, Sadchikov A, Schüll D, Seres Z, Sikora B, Simion V, Smolyankin S, Sodan U, Teh K. Interplay of collective flow phenomena and velocity correlations of intermediate-mass fragments in collisions of Au+Au at E=(100-400)A MeV. Phys Rev C Nucl Phys 1995; 51:2686-2699. [PMID: 9970355 DOI: 10.1103/physrevc.51.2686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
50
|
Jundt F, Herr I, Angel P, Zur Hausen H, Bauknecht T. Transcriptional control of human papillomavirus type 18 oncogene expression in different cell lines: role of transcription factor YY1. Virus Genes 1995; 11:53-8. [PMID: 8808335 DOI: 10.1007/bf01701662] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Binding of YY1 to the proximal fragment of the human papillomavirus type 18 (HPV-18) upstream regulatory region (URR) activates the oncogene expression of HPV-18 in HeLa cells, whereas in HepG2 cells this expression is repressed by YY1. In the present transient transfection study, we analyze the regulation of the HPV-18 URR by YY1 in an extended number of cell lines. Except for HeLa cells, YY1 represses or does not influence oncogene expression in all cell lines tested. In HeLa cells the activation of viral oncogene expression by YY1 is caused by the functional interplay between YY1 and a factor binding to the newly identified "switch region" of the HPV-18 URR. In this work we show that in HeLa cells, a 22 bp region located between the "switch region" and the promoter proximal fragment contributes to the modulation of the activity of YY1 and, in addition, regulates HPV-18 promoter activity independently of YY1.
Collapse
Affiliation(s)
- F Jundt
- Forschungsschwerpunkt Angewandte Tumorvirologie, Heidelberg, Germany
| | | | | | | | | |
Collapse
|